We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · March 15, 2021

Second-Line Eltrombopag in Adults With Primary Immune Thrombocytopenia to Achieve Sustained Remission Off-Treatment

British Journal of Haematology

 

Additional Info

British Journal of Haematology
Eltrombopag Second-Line Therapy in Adult Patients With Primary Immune Thrombocytopenia in an Attempt to Achieve Sustained Remission Off-Treatment: Results of a Phase II, Multicentre, Prospective Study
Br. J. Haematol 2021 Feb 22;[EPub Ahead of Print], E Lucchini, F Palandri, S Volpetti, N Vianelli, G Auteri, E Rossi, A Patriarca, G Carli, W Barcellini, M Celli, U Consoli, F Valeri, C Santoro, E Crea, M Vignetti, F Paoloni, CL Gigliotti, E Boggio, U Dianzani, I Giardini, M Carpenedo, F Rodeghiero, R Fanin, F Zaja, for Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading